紫杉醇加顺铂的新辅助化疗对提高ⅢA期非小细胞肺癌手术切除率的临床作用

Clinical effects on the neoadjuvant chemotherapy of paclitaxel plus cisplatin for improving the surgical resection rate of stage ⅢA non-small cell lung cancer

目的探讨紫杉醇加顺铂(TP方案)的新辅助化疗对提高ⅢA期非小细胞肺癌(NSCLC)手术切除率的影响。方法46例ⅢA期NSCLC患者随机分为新辅助化疗组(23例)和单纯手术组(23例)。新辅助化疗的患者确诊后即接受2个周期全身化疗然后手术。单纯手术组患者确诊的直接手术治疗。结果新辅助化疗有效率为56.5%,化疗毒副作用较轻,患者可以耐受。新辅助化疗组的手术切除率为95.6%,根治切除率为60.8%,明显高于单纯手术组患者(P<0.05)。后者的手术切除率和根治性切除率分别为73.9%和30.4%。新辅助化疗并未增加手术并发症。结论新辅助化疗可明显提高ⅢA期NSCLC患者的手术切除率和根治切除率。

Objective To investigate the effect of neoadjuvent chomotherapy of paclitexel plus eisplatin for improving the surgical resection rate of stage ⅢA non-small cell lung cancer(NSCLS).Methods 46 patients with stage ⅢA NSCLC were randomly divided into neo a djuvant chemotherapy group(23 cases)and simple operative group(23 cases).Neoadjuvant chemotherapy group(NCG)received two-cycle chemotherapy and then underwent operation.Simple operative group(SOG)was only treated by operation.Results The effective rate of NCG was 56.5%. It′s side effects was less.The patients could tolerate this treatment:The operative resection rate of NCG was 95.6%.Radical resection rate was 60.8%. It was higher obviously than that simple operative group(SOG)(P < 0.05).The operative resection rate and radical resection rate of were 73.9% and 30.4% respectively in the latter group.The operative complicatians were not increased in the NCG.Conclusion The neoadjuvant chemotherapy can improve obviously the operative resection rate and radical resection for patients with NSCLC.